Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery

다국어 초록 (Multilingual Abstract)

Purpose: Local recurrence is a major concern in patients who have undergone surgery for ductal carcinoma in situ (DCIS). The present study assessed whether the expression levels of hormone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67, as well as resection margin status, tumor grade, age at diagnosis, and adjuvant hormonal therapy and radiotherapy (RT) are associated with recurrence in women with DCIS. Methods: In total, 111 patients with DCIS were included in the present study. The invasive and noninvasive recurrence events were recorded. The clinicopathological features; resection margins; administration of hormonal therapy and RT; expression statuses of estrogen receptor (ER), progesterone receptor (PR), and HER2; Ki-67 expression; and molecular subtypes were evaluated. Logistic regression analysis was performed to examine the risk factors for recurrence. Results: Recurrence was noted in 27 of 111 cases (24.3%). Involvement of resection margins, low tumor grade, high Ki-67 expression, and RT were independently associated with an increase in the recurrence rate (p<0.05, Pearson chi-square test). The recurrence rate was not significantly associated with patient age; ER, PR, and HER2 statuses; molecular subtype; and hormonal therapy. Conclusion: The results of the present study suggested that the involvement of resection margins, low tumor grade, high Ki-67 index, and the absence of adjuvant RT were independently associated with increased recurrence in patients with DCIS. Future studies should be conducted in a larger cohort of patients to further improve the identification of patients at high-risk for DCIS recurrence.

참고문헌 (Reference)

1 McCahill LE, "Variability in reexcision following breast conservation surgery" 307 : 467-475, 2012

2 Wang SY, "Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis" 127 : 1-14, 2011

3 Cornfield DB, "The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone" 100 : 2317-2327, 2004

4 Rakovitch E, "The management of ductal carcinoma in situ of the breast: a screened population-based analysis" 101 : 335-347, 2007

5 Silverstein MJ, "The influence of margin width on local control of ductal carcinoma in situ of the breast" 340 : 1455-1461, 1999

6 Alvarado M, "The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS scoreTM result" 111 : 935-940, 2015

7 Scholzen T, "The Ki-67 protein: from the known and the unknown" 182 : 311-322, 2000

8 Solin LJ, "Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast" 30 : 3-9, 1994

9 Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update" 31 : 3997-4013, 2013

10 Benson JR, "Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery" 14 : e348-e357, 2013

11 Zhang X, "Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis" 25 : 19-28, 2016

12 Fisher ER, "Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma" 86 : 429-438, 1999

13 Silverstein MJ, "Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast" 16 : 1367-1373, 1998

14 Tolles J, "Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma" 13 : R51-, 2011

15 Febbo PG, "NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology" 9 (9): S1-S32, 2011

16 Sharaf Aldeen B, "Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome" 37 : 474-478, 2013

17 Williams KE, "Molecular phenotypes of DCIS predict overall and invasive recurrence" 26 : 1019-1025, 2015

18 Muggerud AA, "Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer" 4 : 357-368, 2010

19 Wapnir IL, "Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS" 103 : 478-488, 2011

20 Hughes LL, "Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group" 27 : 5319-5324, 2009

21 Douglas-Jones AG, "Effect of margins of excision on recurrence after local excision of ductal carcinoma in situ of the breast" 55 : 581-586, 2002

22 Deyarmin B, "Effect of ASCO/CAP guidelines for determining ER status on molecular subtype" 20 : 87-93, 2013

23 Ernster VL, "Detection of ductal carcinoma in situ in women undergoing screening mammography" 94 : 1546-1554, 2002

24 Sari E, "Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer" 28 : 57-63, 2011

25 Silverstein MJ, "Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index" 2010 : 193-196, 2010

26 Ringberg A, "Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics" 37 : 1514-1522, 2001

27 Provenzano E, "Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast" 39 : 622-630, 2003

28 Boxer MM, "A review of the management of ductal carcinoma in situ following breast conserving surgery" 22 : 1019-1025, 2013

29 Silverstein MJ, "A prognostic index for ductal carcinoma in situ of the breast" 77 : 2267-2274, 1996

30 Solin LJ, "A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast" 105 : 701-710, 2013